Reuters logo
BRIEF-Merrimack stops Phase 2 Hermione trial of MM-302 in Her2-positive metastatic breast cancer patients
December 21, 2016 / 12:23 PM / in a year

BRIEF-Merrimack stops Phase 2 Hermione trial of MM-302 in Her2-positive metastatic breast cancer patients

Dec 21 (Reuters) - Merrimack Pharmaceuticals Inc

* Merrimack Pharmaceuticals Inc says now plans to provide results of ongoing strategic pipeline review in January

* There were no new or unexpected safety concerns

* Merrimack - Decision to stop trial was made following DSMB’s opinion that continuing would be unlikely to demonstrate benefit over comparator treatments

* Merrimack Pharmaceuticals Inc says both treatment and control arms were found to have shorter than expected median progression free survival

* Merrimack stops the Phase 2 Hermione trial of MM-302 in Her2-positive metastatic breast cancer patients Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below